ReviewJournal of experimental & clinical cancer research : CR2014
Hepatic arterial embolization in patients with neuroendocrine tumors.
Review in Journal of experimental & clinical cancer research : CR, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- A new angiographic imaging platform reduces radiation exposure for patients with liver cancer treated with transarterial chemoembolization.European radiology · 2015Trial
- Treatment of Pancreatic Neuroendocrine Tumors: Beyond Traditional Surgery and Targeted Therapy.Journal of clinical medicine · 2025Review
- Review
- Liver-Directed Locoregional Therapies for Neuroendocrine Liver Metastases: Recent Advances and Management.Current oncology (Toronto, Ont.) · 2024Review
- Article
- Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms.Endocrine-related cancer · 2023Article
- Neuroendocrine Tumors: Genomics and Molecular Biomarkers with a Focus on Metastatic Disease.Cancers · 2023Review
- External Validation of a Clinical Score for Patients With Neuroendocrine Tumors Under Consideration for Peptide Receptor Radionuclide Therapy.JAMA network open · 2022Article
- Drug-eluting bead chemoembolization for the treatment of nonresectable hepatic carcinoma in dogs: A prospective clinical trial.Journal of veterinary internal medicine · 2021Article
- Currently available treatment options for neuroendocrine liver metastases.Annals of gastroenterology · 2021Review
- Hepatic Necrosis after Trans-Arterial Embolization of Metastatic Neuroendocrine Tumour.European journal of case reports in internal medicine · 2020Article
- Non-Pharmacological Therapeutic Options for Liver Metastases in Advanced Neuroendocrine Tumors.Journal of clinical medicine · 2019Review
- Hepatic intra-arterial therapies in metastatic neuroendocrine tumors: lessons from clinical practice.Endocrine · 2018Article
- Selective internal radiation therapy: an effective treatment for hormonal syndromes in pancreatic neuroendocrine tumors.Hepatic oncology · 2018Article
- Liver transarterial embolizations in metastatic neuroendocrine tumors.Reviews in endocrine & metabolic disorders · 2017Review
- Association of hepatic vein Lipiodol tram-track sign during transcatheter arterial chemoembolization with perioperative death.The Journal of international medical research · 2017Article
- Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies.Expert opinion on pharmacotherapy · 2016Review
- Feasibility of a Modified Cone-Beam CT Rotation Trajectory to Improve Liver Periphery Visualization during Transarterial Chemoembolization.Radiology · 2015Article
- Arterial Therapies of Non-Colorectal Liver Metastases.Viszeralmedizin · 2015Review
- Negatively charged AuNP modified with monoclonal antibody against novel tumor antigen FAT1 for tumor targeting.Journal of experimental & clinical cancer research : CR · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver metastases occur in 46-93% of patients with neuroendocrine neoplasms (NENs). Presence and extension of liver metastases are considered important prognostic factors, as they may significantly impair the patient's quality of life, because of either tumor bulk or hormonal hypersecretion. Therapies for NEN liver metastases include surgical resection, liver transplantation, chemotherapy and biotherapy. Surgery is the gold standard for curative therapy, but in most of NEN patients with liver metastases, when surgery can not be applied, minimally invasive therapeutic approaches are adopted. They include trans-arterial embolization (TAE), trans-arterial chemoembolization (TACE), radiofrequency thermal ablation and new emerging techniques.TAE is based on selective infusion of particles in the branch of the hepatic artery supplying the tumor lesions. The goal of TAE is to occlude tumor blood vessels resulting in ischemia and necrosis. Many reports have shown that TAE can reduce tumor size and hormone output, resulting in palliation of symptoms without the use of cytotoxic drugs, resulting in better tolerability. This review will focus on TAE performance and safety in NEN patients with liver metastases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.